Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 22,018 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Cataract
Interventions: Argos with Alcon Image Guidance Biometer, IOLMaster 700 Biometer, Unity DX and SMARTCataract DX (SCDX) Biometer; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Facet Joint Arthropathy, Osteoarthritis, Pain
Interventions: Spinal angiography and embolization/ Embozene Microspheres; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Gait, Spinal Cord Injury (SCI)
Interventions: NNP-LE; Device
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Bladder Cancer
Interventions: Durvalumab, Romidepsin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Bone Marrow Transplant, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Stem Cell Transplant
Interventions: Enhanced Usual Care (Control) Website, Intervention website; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Nutley, New Jersey

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
Interventions: Cone-Beam Computed Tomography, Hypofractionated External Beam Radiation Therapy, Questionnaire Administration, Radiation Boost, Whole Breast Irradiation; Procedure · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Arcadia, California • Duarte, California • Irvine, California + 4 more

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: Mezagitamab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 25
States / cities: Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more

Conditions: Extra-Pancreatic Neuroendocrine Tumor (epNET), Pancreatic Neuroendocrine Tumor (pNET)
Interventions: Everolimus, Zanzalintinib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Asthma
Interventions: Placebo, Tozorakimab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 65
States / cities: Bakersfield, California • Huntington Beach, California • La Mesa, California + 61 more

Conditions: Ureteral Stent-Related Symptom
Interventions: Dexamethasone Sodium Phosphate Injection 20 mg, Dexamethasone Sodium Phosphate Injection 4mg; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Docetaxel, Ifinatamab deruxtecan, Prednisone, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 55
States / cities: Phoenix, Arizona • Clovis, California • Duarte, California + 43 more

Conditions: Age-Related Macular Degeneration
Interventions: Retinal Imaging; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Atlanta, Georgia • Fargo, North Dakota • Erie, Pennsylvania + 5 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue, Testosterone cypionate, ZEN-3694; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm, Malignant Pelvic Neoplasm, Metastatic Childhood Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium, Surgical Procedure; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
Interventions: Non interventional study; Other
Lead sponsor: ARCE Therapeutics, Inc.; Industry
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 3
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina • Houston, Texas

Conditions: Congenital Heart Disease (CHD)
Interventions: 2 mL SunButyrate-TG, 4 mL SunButyrate-TG, Placebo; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 1 Month to 3 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)
Interventions: Genicular Artery Embolization, Lipiodol, Simple angiogram; Procedure · Device
Lead sponsor: University of Utah; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab, Sonrotoclax, Zanubrutinib; Procedure · Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Inflammatory Bowel Syndrome
Interventions: ALPCO Calprotectin CLIA; Device
Lead sponsor: American Laboratory Products Company; Industry
Eligibility: 22 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Miami, Florida • Salem, New Hampshire • Westlake, Ohio

Conditions: Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Glofitamab, Obinutuzumab:, Polatuzumab, Rituximab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more

Conditions: Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions: Albumin-Bound Paclitaxel, Dacarbazine, IMA203, ipilimumab, lifileucel, nivolumab, nivolumab plus relatlimab, paclitaxel, paclitaxel plus carboplatin, pembrolizumab, temozolomide; Drug · Biological
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more

Conditions: Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis, Systemic Sclerosis
Interventions: Cyclophosphamide, Fludarabine, NKX019; Drug
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Plantation, Florida • Tampa, Florida + 9 more

Conditions: Early Parkinson Disease (Early PD), Idiopathic Parkinson Disease, Parkinson, Parkinson Disease, Parkinson Disease, Idiopathic
Interventions: NEU-411, Placebo; Drug · Other
Lead sponsor: Neuron23 Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more

Conditions: Focal Segmental Glomerulosclerosis, Membranous Nephropathy, Minimal Change Disease
Interventions: ManNAc; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 115 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Capella Scientia Development Study

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy

Implant for Walking After Incomplete SCI

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Mosaic Trial for Stem Cell Transplant Recipients

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Dexamethasone for Ureteral STent Symptoms (DUSTS)

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

The COSMYC Trial (COmbined Suppression of MYC)

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids

Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases